perrigo co plc (prgo) earnings report: q2 2015 conference...
TRANSCRIPT
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page1of22
PERRIGOCOPLC(PRGO)EarningsReport:Q22015ConferenceCallTranscriptThefollowingPERRIGOCOPLCconferencecalltookplaceonAugust5,2015,10:00AMET.Thisisatranscriptofthatearningscall:
CompanyPart icipants
ArthurJ.Shannon;Perrigo;VP-IR&GlobalCommunicationsJosephC.Papa;Perrigo;Chairman,President,CEOJudyL.Brown;Perrigo;CFO,EVP
OtherPart icipants
LouiseChen;GuggenheimSecurities;AnalystRandallS.Stanicky;RBCCapitalMarkets;AnalystSumantS.Kulkarni;BankofAmericaMerrillLynch;AnalystDavidW.Maris;BMOCapitalMarkets;AnalystMarcGoodman;UBSSecurities;AnalystGreggGilbert;DeutscheBankSecurities;AnalystLindaBoltonWeiser;B.Riley;AnalystElliotWilbur;RaymondJames&Associates;AnalystJasonM.Gerberry;LeerinkPartners;AnalystAnnabelE.Samimy;Stifel,Nicolaus&Co;AnalystEmilChen;MorganStanley&Co;AnalystJamiRubin;GoldmanSachs&Co;Analyst
MANAGEMENTDISCUSSIONSECTION
Operator :
Goodmorning.MynameisKayla,andIwillbeyourconferenceoperatortoday.AtthistimeIwouldliketowelcomeeveryonetothePerrigoCompanyPlcSecondQuarterCalendarYear2015ResultsConferenceCall.Alllineshavebeenplacedonmutetopreventanybackgroundnoise.Afterthespeakers'remarkstherewillbeaquestion-and-answersession.(OperatorInstructions).
Iwillnowhandtoday'scallovertoMr.ArtShannon.Pleasegoahead,sir.
ArthurJ.Shannon (VP-IR&GlobalCommunications):
Thankyouverymuch,Kayla.WelcometoPerrigo'sSecondCalendarQuarterEarningsCall.Acopyoftheearningsreleaseweissuedthismorningisavailableonourwebsiteatperrigo.com.Alsoonourwebsiteistheslidepresentationforthiscall.AsyouknowPerrigobelievesinbeingtransparentandopentoourinvestors.Followingtoday'sconferencecallwewillbeactivelyreachingouttoinvestorsoverthenextfewweeks.
BeforeweproceedwiththecallI'dliketoremindeveryonethatduringtheprocessofthiscall,managementwillmakecertainforward-lookingstatements.PleaserefertotheimportantinformationforinvestorsandshareholdersandSafeHarborlanguageregardingthesestatementsinourpressreleaseissuedthismorning.Followingmanagement'sreviewofthepresentationwewillopenupthecallfor
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page2of22
questions.
I'dliketonowturnthecallovertoPerrigo'sChairmanandCEO,JoePapa.
JosephC.Papa(Chairman,President,CEO):
Thankyou,Art,andwelcomeeveryonetoPerrigo'sSecondQuarter2015EarningsConferenceCall.AlsojoiningmetodayisJudyBrown,Perrigo'sExecutiveVicePresidentandChiefFinancialOfficer.
ForouragendatodayfirstIwillmakeafewcommentsonthequarter.NextJudywillgothroughthedetailsofthesecondquarterresults.ThenIwillgiveyouanoverviewofourrecentsuccessinbothstorebrandandprescriptionproductapprovals.Andfinally,reiterateourpositiononMylan'sunsolicitedoffertoacquirePerrigo.Finally,youwillhaveanopportunityforquestionandanswers.
Beforewegetintotheagendahowever,I'dliketostartbythankingPerrigoemployeesfortheirdiligentfocus,whichhasledtoadjustednetincomegrowthof37%.Evenwithallthenoiseyou'vebeenfollowingoverthepastfewmonths,ournearly13,000PerrigoemployeeshaveannouncedthreeM&Atransactions,deliveredonourOmegaintegrationplans,achievedgreatoperationalefficienciesandproductivityimprovement,executedonournewproductlaunches,anddeliveredonourBasePlusPlusPlusstrategy.It'sgreatworkbytheteam.
Nowlet'sdiscussthequarter.Onslide4youcansee,despitesomechallenges,thisisaverystrongquarter.Ourquarterlyperformanceishighlightedbysecondquarterrecordnetsalesofmorethan$1.5billion.Wealsoachievedrecordadjustedgrossmargin,recordadjustednetincome,andrecordoperatingcashflow.
OurConsumerHealthcaresegmentgrewadjustedoperatingincomeanimpressive18%comparedtolastyear.Infactourconsumerfacingrevenuesnowrepresent75%ofthetotalPerrigocompanyrevenues.
Movingontoslide5youcanseeconsolidatedPerrigogrewthetoplineby34%.ThisisdrivenprimarilybytheadditionoftheBrandedConsumerHealthcare,orBCH,segmentsalesandtherecordsecondquartersalesintheRxbusiness.
Newproductscontributed$149million,comprising$116millioninlegacyPerrigosalesand$33millioninourOmegabusiness.Youalsoseethatwecontinuedtoinvestinourfuturethisquarter.Weinvestedover$44millioninR&Dtocontinuetosupportourstrongestnewproductpipelineever.I'dliketohighlightthatevenwithstrongR&DinvestmentsinourlegacyPerrigobusiness,supplychainandmanufacturingefficienciesandfavorableproductmixallowedustoachieverecordsecondquarterorganicadjustedoperatingincome,whichimproved11%overlastyear.
Judywillgiveyoumoredetails,butletmehighlightafewitemsfromthebusinesssegments.Ourconsumerfacingbusinesssegments,bothConsumerHealthcareandourBrandedConsumerHealthcaresegments,hadcombinednetsalesof$1.15billionthisquarterwithadjustedgrossmarginsofnearly42%.Theircombinedadjustedmarginswerenearly--operatingmarginswerenearly21%.Newproductsfortheconsumerfacingbusinesseswere$110millioninthequarter.
Inthequarterwewereabletorealizegross--positivegrossprofitmarginimprovementfromnewproductsnetofdiscontinuedproducts.
TheglobalizationandscaleofourconsumerfacingbusinessplatformprovidesexcitingnewopportunitiesforPerrigo,asevidencedbythethreerecentlyannouncedacquisitionsinourconsumerbusiness.
First,weannouncetheacquisitionoftheMexicoPatheonsoftgelbusiness,whichclosedinMay.Perrigohaslongdesiredtobeaprimemanufacturerofsoftgelproducts,andthisacquisitiongivesusourentry
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page3of22
point.
Second,weannouncedtheacquisitionofbrandassetsfromGSK.Thisportfoliogeneratedover$110millioninannualsaleslastyear.Andwiththereturninthenicotinelozenges,weexpecttogrowthosesales.
AlsoweannouncedtheacquisitionofGermany'sleadingdietarysupplementbrand,Yokebe,whichismarketedasamealreplacementproductandiscurrentlythesecondlargestdietarybrandbymarketshareinGermany.WeexpecttocloseboththeGSKandtheYokebetransactionsinthethirdquarter.
WiththerecordadjustedoperatingincomeinourConsumerHealthcarebusiness,thestrongperformanceofourrecentlyacquiredbePan-EuropeanOmegabusiness,andtheserecentlyannouncedtransactions,whichboltonverynicelytoourexistinginfrastructure,I'mexcitedbythefutureprospectsandourmegatrendinthistrulyglobalconsumerbusinessplatform.
Asyoucanseeonslide6,newproductswilldriveourfuturegrowth.ExcludingtheimpactofOmegaweexpect$1billioninnewproductlaunchesoverthenext3years,representingmorethan$3.6billioninnationalbrandsales,highlightedbythelaunchesofNasacort,Flonase,theMucinexfamily,plusmanymore.
AlsojustinthelastweekwereceivedthreeANDA'sapprovals.First,wejustreceiveFDAfinalapprovalfortestosteronetopicalgel,1.62%.Second,wereceivedFDAfinalapprovalforibuprofensodiumtabletANDA,thenationalbrandequivalenttoAdvilfastrelief.AndfinallyreceivedFDAapprovalforomeprazolemagnesiumtablet,theequivalenttoPrilosecOTC.Thisisthefirstandonlytrulyequivalentgenericproducttothenationalbrand.ThankyoutoourR&Dteamfortheexcellentwork.
OurRxsegmentonceagainachievedrecordresults,growingsales10%witharecordadjustedgrossmarginof65%.NewproductsalesinthequarterweredrivenbythegenericversionsofclobetasolsprayandourABratedAndroGel1%,bothofwhicharepowerfullaunchesinourRxbusiness.Adjustedoperatingmarginswerestronginthissegmentevenasweinvested$20millioninresearchanddevelopmentandcontinuedmakinginvestmentsinourbrandedRxsalesteam.CongratulationstotheRxteamforanotherstrongquarter.
InSpecialtyScienceswehavebeenverypleasedwiththemarketperformanceofTysabri.Itisagreatassetthatisgeneratingterrificcashflow,particularlywiththecurrent18%royaltythatitnowprovides.
Asyoucanseeonslide7overthelast52weeksU.S.storebrandscontinuetogainshareinsmokingcessation.Whenyoutakeouttheimpactofnewnationalbrandproductlaunchesandtheeffectofnationalbrands'returntothemarket,storebrandmarketsharecontinuestogrow.
GiventhemegatrendsI'vetalkedaboutformanyyears,includinganagingpopulation,increaseduseofmedicationsasindividualsgetolder,andrisinghealthcarecosts,Perrigoiswellpositionedtomeetthefutureneedsfortheglobalhealthcarecommunity.
NowletmeturnthecallovertoJudy.
JudyL.Brown (CFO,EVP):
Thanks,Joe.GoodmorningeveryoneandwelcometoourfirstearningsconferencecallwiththeadditionofournewlyformedBrandedConsumerHealthcaresegment,orBCHasI'llrefertoit,establishedaftertheMarch30,2015,closingoftheOmegaPharmaacquisition.
Ithasbeenanextremelybusyquarteronmultiplefronts.WecontinuetoexecuteontheintegrationofOmegaandbroadenourcustomerandpatientreach;furthertheprocessofshiftingourfiscalyearend
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page4of22
fromJunetoDecembertoameliorateyourfinancialanalysesgoingforward;updatedthemarketonourstrategiestoachieveorganic3-yearcompoundannualgrowthratesof5%to10%;announcedthreeacquisitionssinceclosingOmega;receivedtwounsolicitedoffersfromMylantoacquirePerrigo;andcontinuedtoactuallypursuenewcorporatedevelopmentopportunities,allwhileachievingrecordresultsinthequarter.NeveradullmomentatPerrigoandseeminglyneverenoughpagesinourpassports.
BeforewediveintothequarterI'dliketofirstremindyouofourcontinuedfocusonprovidinghighlytransparentfinancialandoperationalresults.WiththeadditionofournewPan-EuropeanBCHsegmentandourfocusoncontinuedgeographicexpansion,wewillnowprovideyouwithconstantcurrencyrevenueinformationtoenableeasieranalysisoftheunderlyingperformanceofourbusinessoutsidetheU.S.
Consolidatedresultsfromourdurablebasebusinessportfolio,bolsteredbythenewly-acquiredBrandedConsumerHealthcaresegment,delivered37%growthinadjustednetincome.Consolidatedadjustedgrossmarginexpanded460basispointsto49.1%withpositivecontributionsfromBCH,supply-chainefficiencies,andoverallpositiveproductmix.
AsJoetalksaboutfrequentlythemoataroundPerrigo'smarginsviaoursupplychainprowesswasclearlyevidentthisquarterasyear-over-yearorganicadjustedgrossmarginexpandedover300basispoints,drivenbyfocusedglobalsourcingandcontinuedmanufacturingefficienciesthroughoutouroperation.
NowI'dliketoturntoourbusinesssegment,startingwithareviewofourresultsinConsumerHealthcareonslide8.AsremindertheCHCsegmentnowincludethelegacynutritionalsaswellasourPDIbusiness,whichhadpreviouslybeenreportedinOther.
SaleswithinCHCweredrivenbypositivecontributionsfromoursmokingcessationfranchise,evenafterthereturntomarketofanationalbrandcompetitor,inclusionofsalesfromstorebrand600mgMucinexERinthequarterversuslastyear,andoverallhighersaleswithinthecough/coldcategoryduetoarelativelylongercough/coldseasonintheU.S.versuslastyear.
Withintheinfantnutritioncategorynetsalesofinfantformulacontinuetoperformwell,ledbyincreasingconsumerappetitefororganicformula,reflectedinhighercontractmanufacturingsalesinthatcategory.Offsettingthesepositivedynamicswere,one,relativelylowersaleswithintheanimalhealthcategoryledbytheabsenceofcontractmanufacturingsalestoanationalbrandaspreviouslydiscussedlastquarter;two,arelativedecreaseinOTCpromotionsthisyearbycertainretailersofamajorproductintheGIcategory;three,continuedpricepressuresfrominternationalcompetitorswithintheVMScategory;andfour,$12millioninforeigncurrencyheadwinds.Infacttheimpactoftheanimalhealth,VMS,andFXitemsIjustmentionedwerea450basispointyear-over-yeartoplineheadwindtothissegment'sgrowth.
Adjustedgrossmarginexpandedtoitshighestlevelinthe6--last6yearsduetogreaterproductionefficiencies,greaterseasonalvolumes,andfavorablecommoditypricing.AtthesametimewecontinuedourspendingdisciplineinSG&A.Andasaresultadjustedoperatingmarginincreased390basispointyearoveryear,whichledtotheimpressive18%growthinadjustedoperatingincomecomparedtolastyearthatJoejustmentioned.
Onslide9youcanseethatnetsaleswithinBrandedConsumerHealthcarewere$401millionforthequarter,anall-timerecordquarterforOmegaPharma.Thisimpressiveresultwasdrivenbyan11%increaseinsalesofthetop20brandsonaconstantcurrencybasisversuslastyearandthelaunchofanumberofexcitingnewproducts,includingXLSMaxStrength,alineextensiontothebrandSLXMedicalforweightloss;newversionsandflavorsofBronchostop,anherbalcoughmedicine;andstrongdistributionsalesinthequarter.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page5of22
Turningtoslide10youcanseethatourRxteamcontinuedtodeliver,posting10%netsalesgrowthtoarecord$278millioninthequarter.Newproductlaunchesandcontributionfromourwomen'shealthbrandedcategoryledtorecordadjustedgrossprofitforthesegment.WecontinuetoinvestinhighmarginpotentialR&Dprojects,highlightedbyanapproximate38%increaseinyear-over-yearR&Dinvestmentstoalevelof7.2%ofRxnetsales.
Turningtoslide11SpecialtySciencesnetsaleswere$84million,comprisedofTysabriroyaltiesat18%fortheentirequarter,versusonly2monthsatthat18%levelayearago.Year-over-yeargrowthwaslimitedbytwodynamics,one,foreign-exchangenegativelyimpactednetsalesbyapproximately$7million,andtwo,secondcalendarquarter2014netsalesincludedapproximately$10millioninnetsalesfromBiogen'sagreementwiththeItalianMedicinesAgency.
BeforeIturntotheforecastaquickcommentonthebalancesheet.AsofJune27,2015,totalcashonthefaceofthebalancesheetwas$786millionandcurrentandlong-termdebtwas$5.3billion.Netcashflowfromoperationsonatrailing12-monthbasiswasarecord$1.2billion.
Movingintotheupdatedcalendar2015guidanceonslide12.First,I'dliketostartwithnotingthatweareconfirmingourcalendaryearconsolidatednetsalesandadjustedearningspershareguidanceweprovidedyouonApril21.TohelpyoufurtherrefineyourmodelsI'dliketoprovideyouwithsomeaddedcoloronthesegmentsforcalendar2015.
Duetopreviously-discussedseasonalityinConsumerHealthcare,specificallyintheanimalhealthandcough/coldcategories,weexpecttheadjustedoperatingmarginrealizedinthissegment'spastquartertobethehighestfortheyear.Asisourhistoricaltrendinthissegment,volumesinthesecondhalfofthecalendaryearareanticipatedtoberelativelyloweroverthenexttwoquarters,thusproducingrelativelyloweradjustedoperatingmargininthesecondhalfofthecalendaryearinlinewithpastseasonalperformance.AdditionallyweanticipateR&Dspendtoincreaseapproximately30%inthesecondhalfofthecalendaryearrelatedtoprojecttiming.
WecontinuetoexpectBrandedConsumerHealthcaretocontributeapproximately20%oftotalPerrigoconsolidatednetsalesforthefullyearwithstrongnetsalesovertheremainderofcalendar2015.NotethatthoughourforecastinthisnewbusinessanticipatesthattheJunequarterjustendedwillbethehighestrevenuequarterinthecalendaryear,duetonewproductlaunchessuchasXLSMaxStrengthandstrongdistributionsaleswejustrealizedinthatparticularperiod.NotealsothatthecurrentBCHforecastnowdoesinclude$25millioninnetsalesassociatedwithrecentlyannouncedacquisitions,whichweexpectwillcloseintheSeptemberquarter.
GiventhecontinuedpositivemomentumintheRxbasebusiness,coupledwithstrongrecentproductlaunches,weremainexcitedaboutthissegment'sgrowthprospects.PleasenotethatfortheremainderofthecalendaryearadjustedgrossmarginsinRxarealsoexpectedtobeslightlysofterthanthispastquarter,duetoproductmixandlimitednewproductlaunchesfortheremainderofthecalendaryear.
Turningtoslide13.Whiletheadjustedannualeffectivetaxrateisstillexpectedtobeapproximately17%forthefullcalendaryear2015,weanticipateboththethirdandfourthcalendarquarterratestoincreasetoapproximately18.5%duetotheinclusionofestimatedearningsbeforetaxfromOmegaPharma.Thisjumpintherateisafunctionoftheaccountingrulessurroundingannualizingeffectivetaxrates.
Pleaserealizethatforaccountingpurposesthe6-monthstubperiod,orsecondhalfofcalendar2015,isthefirsttimeOmegaresultswillbeincludedforafullU.S.GAAPreportingcycle.Thefirsthalfofcalendar2015wasstilltechnicallypartofourfiscal2015reportingyear,whichincludedOmegaforonlyonequarter.Thisestimated18.5%adjustedtaxrateisinlinewiththeexpectationsfromourNovember6Omegaacquisitionannouncementcall.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page6of22
Sosummingallthisinformationupattheconsolidatedlevel,weexpectthirdcalendarquarter2015adjustednetincometogrowbetween30%and35%overthecomparable2014period.Foryourcalculationsofearningspersharepleasecontinuetomodeldilutedsharesoutstandingofapproximately147millionsharesinthequarter.
AsIstatedafewmomentsagothesearecertainlyveryexcitingtimesatPerrigo,bothintermsofreachingnewcustomersaroundtheglobeandexecutingourBP3[BasePlusPlusPlus]strategy.Yetagainwe'vedeliveredremarkableyear-over-yearadjustednetincomeperformance,37%thisquarter,comingoff41%growthintheMarchquarter,withexpectedgrowthnextquarteragainnorthof30%.
AtthesametimerecordcashflowswillcontinuetoprovidemeaningfulreturnstoshareholdersandaswellastheycreatethedrypowdertoenablemeaningfulM&Aandthemultipliereffectthesetransactionscanachieve.
NowI'dliketoturnthecallbacktoJoe.
JosephC.Papa(Chairman,President,CEO):
Thankyou,Judy.BeforeweopenituptoQ&A,Iwanttojustprovideafewthoughts.
First,IwanttorepeattheexcitingnewsthatwereceivedthreeANDAapprovalswithinthelastweek.Thatisgreatnews.AndtomyrecollectionisarecordforPerrigo.AndimportantlyitgivesusincreasedconfidenceinourabilitytoexecuteontheBasePlusPlusstrategy.
Second,ourmanufacturingandsupplychainteamshavedoneagreatjobfindingoperationalefficiencieswithourcontinuousimprovementprogram.Andyou'rereallyseeingitinthebottomlineresultsofourcompany.
Third,IwanttotakeamomenttospeakabouttheunsolicitedofferbyMylantooffer2.3sharesplus$75incashpershareofPerrigo,whichIknowisonalotoftheshareholders'minds.Aswe'vebeensayingsinceAprilwestronglybelievethatMylan'soffersubstantiallyundervaluesPerrigo;isnotinthebestinterestofPerrigoshareholders.Andbothremaintruetoday.WedonotbelievethisisinthebestinterestofPerrigoshareholders.
Ourboard'srejectionofMylan'sofferwasunanimous.AndmadespecificallythatithadnothingtodowithTeva.IthasalwaysbeenastrengthofourstandalonePerrigobusiness.YouhaveseenthisreflectedtimeandtimeagainaswereturnvaluetoourshareholdersbyexecutingonourBasePlusPlusPlusstrategy.
Ouracquisitionstrategycontinuestoprovideamultipliereffecttoouralready-strongorganicgrowth,aswe'veshownwithouracquisitionsofleadingEuropeanbrandsoverthepastfewmonths.ThemarketmovementsfollowingTeva'sannouncementlastweekonlyreinforceourconvictionabouttheMylanoffer.
AlsoPerrigohasastronghistoryofresponsiblecorporategovernancepolicies.Webelievedeeplyinourresponsibilitytoshareholders.Forexamplein2014Perrigoreceivedthebestcomplianceandethicsprogramforalarge-capcompanyandourGeneralCounselToddKingmawontheGovernanceProfessionaloftheYear.GreatachievementforToddandtheentirePerrigocompany.
Butthereisalotofnoiseinthemarket.AndIwanttotrytodistillitdownintoreallythreecommentsontheunsolicitedMylanoffertoacquirePerrigo.SpecificallycombiningwithMylan,numberone,woulddilutethestrengthofourdurableconsumerbusiness.Itwouldriskthevaluethatwecontinuedtocreateforshareholders.
Numbertwo,webelieveitwouldresultinasignificantP/EmultiplecontractionaswetakeourPerrigodurablebusinessandcombineitwiththeMylanbusiness.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page7of22
Numberthree,ImakenostatementaboutthetimingofEpiPengeneric.HoweverclearlyitwouldexposePerrigoifwemergedthetwocompaniestogethertoaproductconcentrationriskofEpiPen.I'llletyoualldecidewhenandifagenericwillshowupofEpiPen.
ImakenopredictionsonhowMylanshareholderswillvoteonAugust28,butIalsowanttoremindeveryoneincludingtheMylanshareholdersthatiftheyproceedwithatenderofferforPerrigo,thiswillnotbetheeasypathtocompletionthatsomearepaintingittobe.Thebarforsuccessinthetenderofferprocessisaveryhigh80%ofalloutstandingPerrigoshares.
We'vebeenontheroadtalkingtoourshareholders,andwearepleasedtohearyourconfidenceinPerrigo'smanagementteamandourstandalonestrategy.Eachofyouwillneedtomakeyourowndecision.Butbasedonthecurrentoffer,ifweevergettoatendershareprocess,IintendtovotenototheMylanunsolicitedoffertoacquirePerrigo.
InclosingwecontinuetobelievethatMylan'soffersubstantiallyundervaluesourbusiness.AndweareconfidentthatbyexecutingonourBasePlusPlusPlusstrategywecandeliverfarsuperiorgrowthtowhatisrepresentedbytheMylanoffer.
Iwillnowopenupthecallforanyquestions.Operatoranyquestions?
QUESTIONS&ANSWERS
Operator :
Pleaselimityourtimetoonequestion.PleaseholdwhilewecompiletheQ&Aroster.AndourfirstquestioncomesfromLouiseChen.
LouiseChen (Analyst-GuggenheimSecurities):
Hi.Thanksfortakingmyquestion.SoonequestionthatweoftengetishowmuchgrowthisleftforPerrigooverthelongerterm,especiallyinlightofsomeofthenewseventsthathavehappenedrecently?Areyoujustatthebeginning,middle,orendofthecompany'sgrowth?Andhowcommittedareyouasamanagementteamtoseethisthrough?Thanks.
JosephC.Papa(Chairman,President,CEO):
So,Louise,thanksforyourquestion.ImeanIthinkthecommentarythatIwillofferisthatweseethegrowthopportunitiesasbeenverysubstantialforthePerrigocompany.Numberone,relativetowherewesitasacompany.Wereallythinkthere'sthreemegatrendsthatcontinuetodrivethebusiness,eachofthemcontributingtothegrowth.
FirstoneisjustwhatIwouldcallthedemographicsandtheintensityofusageofpharmaceuticals.Weexpecttogoupaswe'vejustseengrowthinthepopulation,andmoreimportantlygrowthoftheover65populationthatuses2.7xmorepharmaceuticals.
Numbertwo,weexpectthecontinuedmovementformnationalbrandtostorebrand.That'satrendthatwecontinuetoseeevendespitesomeofthenewlaunchesthathaveoccurred.Wecontinuetoexpecttoseemoreproductsshift--moreconsumersshiftfromnationalbrandtostorebrand.
Andnumberthree,it'sthemovementofnewproductsthataretodayprescriptionmovingover-the-counter.Weexpectthatwillcontinuetoalsocontributetoourgrowth.Sowestillthinkthere'sasignificantgrowthopportunity.
OntopofthatthoughwhatIthink--thesecondpartofyourquestion--isthatweseetremendousopportunitiesnowthatwe'vealignedandacquiredtheOmegaorganization,andwhatthatmeansforus
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page8of22
ontheBrandedConsumerbusiness.
AndimportantlythesamethingsthathavehelpedPerrigogrowinthepast,whereweboltedonincrementalassets.Wethinkwecandothatsamething.WethinktheGSKasset,theYokebeassetarejustthebeginningofthingsthatwecanboltonaswelooktocontinuetogrowthatOmegaasset.
Sowe'rereallyexcitedaboutthefuture.AndIthinkthat'sjustafullreviewofhowexcitedwefeelaboutwherewecangowiththisbusiness.
Operator,nextquestion?
Operator :
OurnextquestioncomesfromRandallStanicky.
RandallS.Stanicky(Analyst-RBCCapitalMarkets):
Great.Thanksguys.Ijusthaveatwopartquestion.First,Joe,youhavespentalotoftimehighlightingyourexposuretowhatI'llcharacterizesasamuchmorestableconsumerandconsumerfacingbusiness.What'syourappetitetoaddmoregenericexposureoutsideofaMylantransaction?Andhowdoyouthinkaboutformulationtechnology,geography,andthenpossiblesize?ThenIhaveonequickfollow-up.
JosephC.Papa(Chairman,President,CEO):
Okay.Soonthequestionofwhatwe'vedone,you'reabsolutelyright.We'vebuiltourbusiness.We'vedonesomeadditionalacquisitions,mostnotablytheOmegaacquisition.Nowthatwe'resittingatapproximately75%ofourrevenuesareverystrongrevenuesinourconsumerfacingbusiness,wethinkthatgivesusaverydurableplatformforthefuture.
ButasI'vesaidinthepastour--Icannotsayitmorestrongly--thatourRxbusinessisaveryuniquebusiness.Itisabusinessmodelwithincredible,incrediblemargins.MostrecentRXmargins--letmejustgetthespecificamount,Idon'twanttogiveyouaninappropriatenumber--butthemostrecentgrossmarginwas64.8%witha49.5%operatingmargin.That'saveryuniqueRxbusiness.
IfIcanfindadditionalassetsthatfitintothat--andthatmeansthatthere'ssomedegreeofdifficultyinproducingthem.Forusithasalwaysbeenextendedtopicals,thingsabsorbedtopically,dermatology,respiratory,nasal,ophthalmic,etcetera,I'mgoingtocontinuetolookforthosetypesofassets.SoIdothinktherearesomeoutthere,andwe'llcontinuetolookforthem.
SoIdon'twanttolimitusonlytoconsumer.IdothinktherearesomeRxassetsthatwouldmakesensetousasacompany,notwithstandingthe--asyousaidtheMylansituationforus.
Isthatwhatyouwerelookingforontheformulationcomment?
RandallS.Stanicky(Analyst-RBCCapitalMarkets):
Great.Yeah.Yeah.Yeah.Justthesecond,orpartBofmyonequestionwouldbejust,youcalledoutonslide7thesmokingcessationandthestorebrandgrowthovernational.AndIjustwantedtogetasense,hasGSKcomeback?Haveyouseenthatimpact?Andareyougrowingthroughthatreturn?AndhowmuchofwhatIthinkisabouta$250millionbaseforyou,howmuchofthatdoyouthinkyoucanholdontoifGSKdoesreturn?
JosephC.Papa(Chairman,President,CEO):
GSKisbackinthemarketplacetobeclear.Andwearecontinuingtogrowthroughthissituation.AndasI
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page9of22
saidinthepartofthecallitisaverygoodbusiness,verylargebusinessforus.Butonethatwethinkhastremendousupsideforusinthefuture,especiallynowaswe'veacquiredtheGSKbrandedassets,notU.S.assets,butexU.S.assets,mostnotablyinEurope.Wethinkthatgivesusanotheropportunitytogrowtheproduct.
OneoftheuniqueitemsaboutPerrigoisnowpairedwithOmegacandosomethingthatOmegacouldn'tdobyitself,Perrigocouldn'tdobyitself.WecouldbuythoseGSKassetsthatwereavailableinEurope.
SonotonlydoweseeitgrowinghereintheUnitedStates,asevidencedbytheIMSortheIRIdata,butalsoweseetheopportunitytogrowoursmokingcessationcategoryinEuropeandaroundtheworld.Sowe'rereallyexcitedaboutit.Wethinkwe'llcontinuetogrowthatbusinessveryconsistentwhatwe'veseenhistorically.
RandallS.Stanicky(Analyst-RBCCapitalMarkets):
That'sgreat.Thanksverymuch.
Operator :
YournextquestioncomesfromSumantKulkarnifromBankofAmericaMerrillLynch.
SumantS.Kulkarni(Analyst-BankofAmericaMerrillLynch):
Thanks.I'mgoingtoaskmyonequestionplus,plus,plus.
JosephC.Papa(Chairman,President,CEO):
Welldone,Sumant.
SumantS.Kulkarni(Analyst-BankofAmericaMerrillLynch):
Howmuchmoreleverageisthereinyoursystemondistributionsellingandadministrativeexpense?AndwheredoyouseetheopportunitiesforcostreductionifthereareanyatPerrigorightnow?
JosephC.Papa(Chairman,President,CEO):
Sure.I'llstart.Judy,youmightwanttoaddtowhatIsay.ButIguessI'llsaywethinkthere'splus,plus,plusopportunity,Sumant.
SpecificallywhatamIsaying?Firstofallontheleveragewe'reseeingisthatthereisnodoubtthataswedoadditionalM&A,wethinkthere'schancestojustgetmoreofitonthetruck,asweshipourtruckfromPerrigotoourlargeretailers.Sothat'sbothhereintheUnitedStates,butalsonowaswe'redoingthoseacquisitions,boltonacquisitioninEurope.Soweclearlythinkthere'sachancetoleverageadditionalmarginorleveragetheP&L.
SecondcommentIwouldsayisthatIdon'twanttomissthechancetosayitonemoretime.ThesupplychainteamfromPerrigoandourentireoperationalandmanufacturinggrouphavejustdoneanoutstandingjobofjustrunningourfacilitiesveryefficientlyandfindingcontinuousimprovementprojectstolowerourcostofgoodssold.ThathasgivenustremendousleverageinourP&LandespeciallyinthemarginstructureasItalkedabout.
OurConsumerHealthcareoperatingmarginthisquarterat21.4%is--it'scertainlyanall-timerecord.AndIthinkreallyreflectsthefactoftheteamjustworkingverywelltotakecostoutofthesystemandallowustoleveragewhatwe'vedoneandhistoricallyandjustdomoreofit.Judy,anythingyouwanttoadd?
JudyL.Brown (CFO,EVP):
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page10of22
TheonlythingIwouldelaborateuponisasyou'reallwitnessingdynamicchangesinhealthcareandlifesciences,you'reseeingdifferentdeliveryprocessesandsystemscomingabout.Andourcustomersandretailerspartneringwithotherstoreachpatientsmoreefficientlyandeffectivelyandbroadenthereachofhealthcare.
Oursupplychainteamanddistributionfolksarealreadyreachingallofthoseplayers.Soasthatdynamismcontinueswe'reabletocontinuetoleverageourrelationshipsandourdistribution--physicaldistributionnetworktoservethesenewly-formedentitiesaswell.Sothatdynamismcontinuestobeservedwiththeassetsthatwehaveandthecompetencythatthisteamhasbuilt.
JosephC.Papa(Chairman,President,CEO):
Yeah.ProbablyonelastcommentI'llmakebeforeyougotoyoursecondpart,Sumant,isthatoftenpeopleaskmeaboutthequestionabout,welltheretailersareputtingmorepressuretogetbetterpricinginthemarketplace.Andthatistrue.
ButpleasemakesurethateveryonerealizesthatwearedoingexactlythatsamethingwithourAPIsuppliers.Weareputtingpressureonthemtogetbetterpricingforourrawmaterials.AndIthinkthat'spartofwhatyou'reseeinghereisthe--ourabilitytotakeadvantageofwhat'vealwaysaffectionatelyreferredtoasamoatandhowwelookatourbusinessandhowwecancontinuetoseekoutadditionalpricingimprovementsforourcostofgoodssold.
Soit'sclearlywethinkanimportantpartofwhatbroughtsomeofthissuccess,andcertainlyonthelegacybusinessrecordoperatingprofits.Didyouhaveasecondpart?
SumantS.Kulkarni(Analyst-BankofAmericaMerrillLynch):
Justonhowmuchcostcouldcomeoutofthesystem.ButIthinkyoutoucheduponthat.
JosephC.Papa(Chairman,President,CEO):
Yeah.Okay.Operator,nextquestion?
Operator :
OurnextquestioncomesfromDavidMarisfromBMOCapitalMarkets.
DavidW.Maris (Analyst-BMOCapitalMarkets):
Goodmorning.Joe,weagreewithyouthattheoffersignificantlyundervaluesPerrigo.ButoneofthethingstheAllegandidwhentheyhadanunsolicitedofferisthattheydrewaverybrightlinebetweenthetwodifferentbusinessmanagementstylesandbusinessmodels.
Someofthat--donealittlebitsofar.ButtodayyoumentionedabitabouthowPerrigohasbestinclasscompliance.
Aftertheearningsbeingoutontheroadtotalkalittlebitaboutthisunsolicitedoffer,isityourintentiontodomaybeastrongerjobinexplainingthedifferences?Doyouseeadifferenceinthecorporatecultures?
Andthenseparatelyifthere'sa--if(inaudible)intheirfavordoyouintendtothenreachouttootherinterestedparties?Andarethereotherinterestedparties?Thankyou.
JosephC.Papa(Chairman,President,CEO):
Soyouaskedalot,David.I'mgoingtotrytogetthroughallofthem.Sofirstofallthankyouforyour
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page11of22
commentaryonsupportingourpositionthatthisofferbyMylansubstantiallyundervaluesthePerrigocompany.
Onthequestionofmanagementstylethere'snodoubttherearedifferencesinthemanagementstyleofthetwocompanies.Ireallydon'twanttogointoanyofthepositivesandnegativesonthisone.Therewillbeatimeandplaceforthatshouldthatgettothepoint.
Ithinkwhatwe'vetriedtofocusonpredominantlyrightnowthoughisthatwe'reveryproudofwhatwe'veaccomplished.We'reveryproudofwinningthecorporategovernancelarge-capcompanyoftheyear.That'ssomethingthatToddandtheentireteamworkedveryhardataccomplishing.Andwe'reveryproudofthingslikethat.
We'reveryproudofourcorporatecultureandwhatwe'veaccomplishedasateam.ThePerrigoteamhasbeentogetherforthemostpart,thisentireteam,we'vebeentogetherforgoingon9yearsnow.Soit'sateamthatknowseachotherverywell,knowshowtogetthingsdone.Andimportantlydeliversonthebottomline.
Yes,wehavechallengeslikeanyotherteam.Butwe'vedoneagreatjobworkingtogetherasateamandachievinggreatresults,bothformakingqualityaffordablehealthcaremoreaffordableforpeopleallovertheworld.
Sowe'reexcited.Andaswethinkaboutfuturethere'sevenmorewethinkwecandotomakethisareality,especiallyknowingthatwethinkwe'reinawinningspotinhealthcare.Wethinkwe'vegotadurablepositionoverthelongterm.
Ifatsomepointthereisa--theMylanteamwinstheirshareholdervote,thenthere'sa--wecantalkmoreaboutitatthattime.RightnowIthinkwewanttostayfocusedoncontinuingtodrivethe--ourBasePlusPlusPlusstrategyforthefuture.
DavidW.Maris (Analyst-BMOCapitalMarkets):
Great.Wellthankyouverymuch.
JosephC.Papa(Chairman,President,CEO):
Thankyou.Operatornextquestion?
Operator :
YournextquestioncomesfromMarcGoodmanfromUBS.
MarcGoodman (Analyst-UBSSecurities):
Morning.Sofirstinconsumer,thediscontinuedsaleswereunusuallyhigh.Canyoujustgiveusalittlemorecoloronthat?
Second,Omega,justremindusfirstofanyseasonalityinthatbusiness.Andsecond...
JosephC.Papa(Chairman,President,CEO):
Yeah.
MarcGoodman (Analyst-UBSSecurities):
Youmentioneddistribution.Howmucharedistributionsalesrelativetolikejustregularconsumerdirectproductsales?OrmaybeIdidn'tunderstandit.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page12of22
Andthenthirdinthegenericsbusiness,justremindusofwhereweareinthispriceincreasedynamic?Andhowsustainableyoufeellikethoseincreasesare?Thanks.
JosephC.Papa(Chairman,President,CEO):
Okay.I'llprobablytakethefirstquestionontheConsumerHealthcareandthethirdquestion.Judy,letmedothembothandthenyoucantalkaboutOmegaandthedistributionandthentheOmegaseasonalityquestion.
SoonConsumerHealthcare,yes,therearediscontinuedproducts.That'sanormalpartofwhatwedoatPerrigo.Letmetrytodescribeit,becauseitisagoodquestionthat--Marc,thatyou'reasking.
Asalwayswecontinuetorefreshourportfoliotostayevenwiththenationalbrandequivalentapproachtoourbusiness.Sothatmeanstherearechangesthatoccurintheportfolio.Soaneasyexampleisinourpethealthcarebusiness.Thisyearweyouknowwelaunchedourfipronilplus.Thatisobviouslyanewproduct,averyexcitingnewproductforus.Andwe'vedonewellwithit.
Havingsaidthatthoughwehadafipronilwith[nobeloron]aspartofourbusiness,astheresultoflaunchingthefipronilwith--plus,wedecidedthatitwasappropriatetodiscontinuesinfipronilnobeloron.We--whenwedothatthoughwefindourselvespromotingproductsorhavinganationalbrandequivalentproduct,whichisalwaysgood.
Alsointhatparticularcaseit'sanationalbrandequivalentproductthathasabettermargin.Sothat'spartofwhat'sdrivingourbottomlineforthisbusinessasweshiftfromoneproducttothenextgenerationofproduct.Wediscontinuetheoldergeneration.It'sanaturalpartofwhatwedoatourcompany.Sothat'sprobablythefirstpartofit.
I'mgoingtogotoyourthirdpartongenericsandpricing,andI'llgobacktoJudyforthesecondone.Onthegenericsandthepricingenvironmentourteamhasdoneagreatjobatlookingatpricing,lookingatbothmakingmoneywhenwe'refirstwithourproduct,whichisanexampleoftheAndroGel1%.AndcertainlyasImentionedtodaywe'lldothesamethingwiththeAndroGel1.62%whenwelaunchthat.Sowegetgoodpricingthere.
Andfinallywegetgoodpricingwhenwe'rethelastoneswiththeproduct,oroneofthelastfewwithproduct.Soacrossthatportfoliowethinkthere'sstillopportunitiestodopricing.We'llcontinuelookatit.Wethinkthere'ssomethingthatwe'llbetalkingaboutinthefutureforpricing.
ButIthinkitreallysupportsthestrengthofthatoperatingprofitlineof49.5%andwhatweachievedwithourRxbusinessinthequarter.Andimportantlythegrossprofitlineis64.8%.
Soforthosereasonswethinkwe'vegotastrongRxbusiness.Andwelooktostillfindsomeadditionalpricingopportunitiesforthefuture.Judy,youwanttotalkabouttheOmegaportionofthequestion?
JudyL.Brown (CFO,EVP):
Yeah.Sure.Sojustbackingup,thequestionwasondistribution.SotheOmegabusinesshashistoricallyhadtheleadingdistributionofgenericsandsomebrandedproductsoutofBelgiumfromtheirhistoricalpresencethere.Andonaproforma,ago-forwardbasisthatwouldrepresentabout15%oftheirrevenues.
Soifyouthinkaboutinpreviouscallswetalkedaboutarunrate,afull-yearannualizedrunrateofOmegaofabout$1.6billion--sorry.$1.6billionrevenuerunrate.About20%wasdistribution.Andonago-forwarditwouldbeabout15%goforward.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page13of22
Andwhenyoutalkaboutseasonality.TheJunequarterwasaverystrongquarter,asImentionedinthepreparedremarks.TheyhadanimportantlaunchintheJunequarter.Andthedistributionsaleswerealsoheavilyseasonal.
Why?Firstofall,youhaveyourcough/coldallergyseasoncomingoff,justlikeintheUnitedStates.Youhavethefocusalsointhesummerofhavingproductsavailableforstocking,becauseifyouknowthebehaviorinEurope,July,August,very,veryheavilyvacation-oriented.Andmanyofthedistributionsystemsmovedifferently.SoyouhavealittlebitmorefocusedseasonalityintheJunequarter.Soit'snotunusualforthatquartertobetheirstrongestoneinEurope.
Sowe'llbetalkingaboutthatonago-forwardbasisaswell,justlikewedoforourprimarilyU.S.ConsumerHealthcarebusiness.Butsufficeittosaytherestoftherunratefortheremainderoftheyear,slightlylower.Newproductlaunchcombinedwithwhatweexpecttobeagood,solidsecondhalfoftheyear.
JosephC.Papa(Chairman,President,CEO):
Thankyou,Marc,foryouquestion.Operatornextquestion?
Operator :
YournextquestioncomesfromGreggGilbertfromDeutscheBank.
GreggGilbert (Analyst-DeutscheBankSecurities):
Thankyouguys.I'llsticktoatwoparter.FirstonCHC,whatcanyoudoorganicallytoimproverevenuegrowthtrendsforCHC?AndinorganicallydoyouseeacquisitionsofsizepotentiallyoutthereforCHCintheU.S.?
Andthesecondpartofthequestion,Joe,wastouchedonearlierbutnotaddressedheadon.Underwhatcircumstanceswouldtheboardofficiallyexploreallstrategicoptionsforthecompany?Orshouldweassumethat'salreadyunderway?AndI'mcurioushowthatplaysintoyourpredictionthattherewouldbea--quote--difficultpathtocompletionbetweenthat50%andthe80%?Thanks.
JosephC.Papa(Chairman,President,CEO):
Sure.OnthequestionoforganicgrowthforCHC,Gregg,always--it's--there'salwaysgoingtobesomeamountofgrowthrelativetojustthedemographicsandpopulation.Justsomeofgrowth,it'sgoingtobefromnationalbrandswitchingtostorebrand.
Butthebiggestpartofthegrowthandthebiggestexcitingpartofthegrowthiswhenwelaunchthosenewproduct.Whenwehaveachanceto--whichwehopeinvery,verynearfuture,certainlyoverthenext12monthsto24months--launchtheequivalentofFlonase,launchtheequivalentofaNexium,aMucinexD,aMucinexfamily,Aratozinesoftgel,justtonameafew.Thosearethebigonesthatwethinkwillhelppropelourgrowth.
Andit'swhywesaidwithconfidencethatweexpecttolaunchover$1billionofnewproductsinthenext3years,whenyouputthesetypesofproductsintothemarketplace.Wethinkthere'sasignificantreturnforourshareholders.
OnthequestionofinorganicConsumerHealthcaregrowth,yes,wedobelievethereissomeadditionalbolt-onsthatareincategoriesthatwe'vetalkedaboutinthepast,adultnutrition,ophthalmics,petcare,diabetes,aretheareaswherewethinkwecanstillsupportsomeadditionalbolt-onswithourbusiness.AndasJudysaidwherewe'regeneratingrecordsamountofcash,wethinkwecanusethatcashtodosomeadditionalbolt-onsandjustmakeourbusinessmorevaluabletothelargeretailers.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page14of22
Onthethirdcomment--orathirdpartofyourquestion,strategicoptions.Wedobelievewehavestrategicoptions.Rightnowwearefocusedonrunningourstandalonebusiness.Wethinkthat'sthemostimportantthingtodoasacompany.Andasyoucanseewe'redoingitquitewellwithwhatwe'veshown,justa34%revenuegrowth,a48%grossmargingrowth,anda35%operatingincomegrowth,a25%EPSgrowth.Wethinkthat'sanimportantpartofoursuccessinthestandalone,andwe'regoingtocontinuetofocusonthat.
Ifinfactthatwegettoapointwherewethinkthereisa--ifMylandoeswintheirshareholdervote,andthere'sinitiationofatenderprocess.Atthatpointwe'dmakesomestrategicdecisionsasaboardastowhat'stherightthingtodoforthecompany.Idoknowthereareothercompaniesthathaveexpressedsomeconversationstome.ButIdon'twanttogotoofartoofast.Ithinkwe'regoingtocontinuetostayfocusedonwhatwe'redoingasacompanyonastandalonebasis.
GreggGilbert (Analyst-DeutscheBankSecurities):
That'shelpfulcolor.Thanksalot.
Operator :
YournextquestioncomesfromLindaBoltonWeiserfromB.Riley.
LindaBoltonWeiser (Analyst-B.Riley):
Hi.Thankyou.SoyougavequiteabitofcolorontheOmegaandthegoodsalesthereandthenewproductsandtheseasonality.ButIwascuriousaboutintermsofthenewproducts,doyouhaveawindowintolikehowdoes2016lookrelativetonewproductsales?Woulditbekindofhigherorlowerthenwhatwe'reseeingin2015?
Andthensecondly,Joe,ifyoucouldjustgivealittlemoreexplanationontheomeprazolemagnesiumapproval?Imeantoconsumersit'sknownasPrilosecOTC,andit'skindoftransparenttothemIthinkwhatit'sactuallymadeof.Soisthatgoingtobeacannibalisticproduct?Orareyouactuallygoingtogetmoreshelfspacebyputtinganotherproductontheshelf?Canyoujustexplainthatalittle?Thanks.
JosephC.Papa(Chairman,President,CEO):
Sure.Soletmejuststartwith--I'llstartwithsomecommentsonournewproductportfolio.And,Judy,ifyouwanttoaddanythingtothatpleasefreetodothat.
Firstofallour--whatIthinkthebestthingIcansayrightnowandwhatwehavesaidoutinthemarketplaceisthatweexpect$1billioninnewproductsoverthenext3years.Themajorityofthoseproductswillbeonourconsumersideaswe'vesaidthat,justrealizingthatapproximately75%ofourrevenueisontheconsumerside.Admittedlythat'slookingatbothOmegaandPerrigotogether.Butthatmajorityofitwillbeontheconsumerside.
TheonlyfinalcommentIwouldsayiswhilewehavenotgivenindividualyear-by-yearcommentary,wedoexpectthenewproductflowtobeapproximatelyathird,athird,andathird.NowitmaymovefromyeartoyearjustsimplyasFDAapprovalscomein.Butit'sapproximatelyathird,athird,andathirdisthewayIwouldcharacterizeit.Obviouslyalittlebitmoreintheouteryears,buttheapproximationathird,athird,andathird.
Onthequestionofomeprazolemagnesiumwethinkit'simportant.It'snot--itwouldbetheveryfirstomeprazolemagnesiumtabletproductinthemarketplace.Astohowwelaunchthatproductandwhatwedowiththeproduct,Ithinkwe'regoingtocontinuetoweighouroptionsonthat.ButtobeclearitistheveryfirsttabletformulationthatisomeprazolemagnesiumequivalenttoPrilosecOTC.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page15of22
Ourproductcontinuestoperformverywell.SoIdon'twanttooverpromiseforthisproduct.ButitisanoptionalalternativeforustothinkaboutaswethinkaboutthefuturemarketplaceforourequivalentofPrilosec.Judy,anythingelseyouwantedtocommentononthenewproducts?Or...
JudyL.Brown (CFO,EVP):
Justwantedtomakesure--alittlecolorthere,Linda.AsJoesaidwe'vehit$1billioninnewproducts,thinkathird,athird,athird.Talkinggreaterthan$300millionnextyear,butthatiswithoutOmega.
Atthisstagewe'restillintheprocessofscrubbingandmakingsurethataswedefinedtheplanfornewproductsthatwe'rehittingthesamedefinition.ButsufficeittosaythattheteamhasquitealonglistofnewproductsopportunitiesbothorganicallyaswellastheirplansforputtinginproductthatiscurrentlyintheI'llcallitU.S.consumerportfolioandpluggingthatintotheirformat.Whichaswe'vetalkedaboutisakeydriveroflong-termfuturerevenuegrowthwithintheOmegaplatform.
Sowehaven'tcalledthatnumberoutyet.Aswegetbetterclaritywewill.Butsufficeittosaythatwillbeaccretivetothe$1billionwe'vetalkedabout.
LindaBoltonWeiser (Analyst-B.Riley):
Great.Thanks.
Operator :
YournextquestioncomesfromElliotWilburfromRaymondJames.
Elliot Wilbur (Analyst-RaymondJames&Associates):
Thanks.Goodmorning.Andyou'vetouchedonthissubjectmatterIguessacoupletimes,butmaybewecouldexploreitinalittlebitmoredetail.BecauseIdothinkit'sanimportanttrendbreakandcertainlywe'llentertainquestionsaboutdurability.
ButspecificallythegrossmarginperformanceintheConsumerHealthcaresegment,obviouslyarecordlevelandwellaboverecentperformancetrends.AndcertainlyPerrigoofnonbelieversIguessovertheyearshavesortofpointedtoabsenceofmarginexpansionevenwithgrowth.Andthisquarterobviouslystandsoutasadramaticexceptionjustsortofthattrend.
Andjustthinkingaboutacoupleofthepush/pullfactorshere,specificallythediscontinuedproducts.Iwouldassumethatthosewererelativelylowmargin.Andalsothecontinuedshrinkageofthecontractmanufacturingbusiness.Thosehadpositiveimpactsonmargintrends,butyoualsotalkedaboutoperatingefficienciesaswell.Somaybejustalittlebitmoregranularitytheresothatwecouldperhapsunderstandthedurabilityoftheperformancethisquartergoingforward?
JosephC.Papa(Chairman,President,CEO):
Okay.So,Elliot,youactuallyknowourbusinessverywell.Icongratulateyou.You'vetouchedonthem.ImeanI...
Elliot Wilbur (Analyst-RaymondJames&Associates):
I'mclearly--Icome--I'mforsale,Joe,attherightprice.Justthrowthatoutthere.
JosephC.Papa(Chairman,President,CEO):
Sogettingbacktothequestion,thegrossprofit,absolutely.Imeanyouhitonit.Very--productmixwasimportant.Wesoldmoreofthehighermargin,lessofthelowermarginitems.Thatobviouslyhasan
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page16of22
impactonrevenueasyouappropriatelypointout.Butwethinkthat'simportantthatwecontinuetostayequivalenttothenationalbrands.Sowefollowthosenationalbrandsveryclosely.Aswegetbetterproductsinthemarketplacewediscontinuesomeproductsthatarejustnotasvaluable.
Numbertwoforusonthisquestionofmixisasthebrandsswitchfromastandardtablettoafastdissolve,wewanttobethere.Wewanttobetherewith--forexamplewejustgottheAdvilquickdissolveorfastreleaseproductapproved.That'sanotherexampleofabrandgoingafteranewformulation.We'refollowing,we'refollowingquickly.We'llhavethatproduct.Andtoourknowledgewe'retheonlyonewiththatproductapproval.Thatwillbeanotherexampleofanupsideopportunityforusrelativetomargin.
Sothosearethingsthatwedoonthemarginsidefor--yes,wediscontinueproducts.Butimportantlywetrytolaunchnewproductsthatarenationalbrandequivalentthathavebetteramarginstructure.
Ontheotherpointofitclearlythoughistheoperatingefficiencyoftheteam,bothfromjustthecontinuousimprovementprojects.Wehavehundredsofcontinuousimprovementprojectsthatwerunthroughtheteam.We'vetriedveryhardtomakethatapartofourDNAatthecompany.AndindeedIthinkwe'vehadsuccessdoingthat.Andwe'llcontinuetolooktotrytogetoperatingleverageinourP&L.
Asafinalpointyoudidn'tmention,Idowanttomakepointofitthoughisthatverymuchasourcustomershavecometousforpricingdiscountsandrebates,etcetera,we'vedonethesamethingwithoursupplychain.We'vesaidtoourrawmaterialssuppliers,listen,wecangetsomeincrementalbusinessbyworkingwithlargecustomerX.Ifwedothatandcandosomethingscanwegetsomeadditionaldiscountsonourcostofgoods?Andindeedwe'vehadsuccessdoingthat.Andwethinkthat'sgoingtobeanimportantpartofourfuture,toyourquestiononwhatwe'rethinkingaboutinourfuture.Judy,anythingIleftout?
JudyL.Brown (CFO,EVP):
Soitwasatremendousmarginquarter,thereisnodoubt.AsIcommentedonearlier,wearestilllookingathavingaverystrongmarginquarterfortheconsumerbusinessasJoepointedout.
Thisquarterwasparticularlygoodwiththevolumesandtheamazingmanufacturingefficienciesthatwesaw.Itreallytranslatedintoabumpinthosemargins.Andweexpectthemtobestrongthroughtheyear.ButasIcommentedmarginwiseitwouldbethestrongestquarterforthecalendaryear.Butlookingstilloverallastrongperformanceingrossprofitfortheyear.
Andthenonanoperatingmarginbasis,againoperatingmarginaswell,secondquarterstrongest.It'sjustwithtimingofR&DspendthattheSG&Acostsavingsandefficienciesthattheteamsawinthisquarterweexpecttocontinuethroughouttherestofthecalendaryearaswell.
Sogoodleanoperatingefficiencyoftheoverallteambothonasalesandmarketingsideandonmanufacturinghavecontinuedtocontributetotheabilityoftheteam,evenwithsomedynamismonthetoplinethatyousawtobeabletoexecutewellonthebottomline.
JosephC.Papa(Chairman,President,CEO):
Operatornextquestion?
Operator :
OurnextquestioncomesfromJasonGerberryfromLeerinkPartners.
JasonM.Gerberry(Analyst-LeerinkPartners):
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page17of22
Hi.Goodmorning.Thanksfortakingmyquestion.SojustcuriousonOmegaIthinkyouprovidedthegrowthofthetop20brandsyearonyear.Justkindofcuriousifyou'dbewillingtoprovidetheyear-on-yeargrowthrelativetotheprioryearquarter?
Andthen,Joe,justcuriouswithPfizerterminatingtheLipitorOTCswitchprogram,justcuriousyourupdatedthoughtsonwhetherthere'slifeforthestatinsintheOTCchannel?Thanks.
JosephC.Papa(Chairman,President,CEO):
Sure.Idon'tknow.Wehaven'tgivenoutspecificnumbersonOmegaforitsgrowth,butitisdoubledigitsIthinkisprobablythewayI'drefresh--rephrasethequestion.
JudyL.Brown (CFO,EVP):
Soonaconstantcurrencybasisthetop20were11%yearoveryear.Forthewholeportfoliodirectionallymid-teenswouldhavebeentheyear-over-yeargrowth.You'vegotsomenoiseintherewithforeigncurrency,etcetera,etcetera,butapproximately14%,15%.
JosephC.Papa(Chairman,President,CEO):
AndthesecondpartofthequestionwasonstatinsandPfizer'sdecisiononLipitor.IthinkasI'vealwayssaidIneverthoughtitwas100%chanceofprobability.Ididsay60/40.
ItappearsthoughthattheresultsofthePfizerclinicaltrialdidnotresultinpatientsgoingontoseetheirhealthcareproviders.Ithinkinthatsituationit'sprobablyunlikelythatstatinswillcometothemarketplace.Ican'truleoutsomebodyelsewilltryitwithanewrefreshmentandviewonit.ButIthinkbasedonthislastattemptbyPfizer,Ithinkit'sprobablyunlikelythatwe'llseestatinsinthenearfuturecometothemarketplaceforOTC.
JasonM.Gerberry(Analyst-LeerinkPartners):
Okay.Thankyou.
Operator :
OurnextquestioncomesfromAnnabelSamimyfromStifel.
AnnabelE.Samimy(Analyst-Stifel,Nicolaus&Co):
Hi.Thanksfortakingmyquestion.IwantedtojusttouchonCHCabitmore.Youkindofansweredthis,butitwassupposedtobeabiganimalhealthquarter,asyouweresellingintothechannelfortheseason.Anditseemsliketherewasactuallysomedeclines.Andyouhadmentionedthatyouhadswitchedoverproduct.
Butasyoulookatanimalhealthisthereasbig--isitasbiganupsideopportunityasyouexpected?AndtowhatextentdoyouneedtosupplementConsumerHealthingeneralwithinorganicgrowth?AndareyouplacingmorepriorityonOmegarightnowandgrowingEuropeanconsumersideasopposedtotheU.S.consumerside?
Andjustaseparatequestiononguidanceclarification.ItdoesordoesnotincludetheGSKproductsandtheGermannutritionals?Thanks.
JosephC.Papa(Chairman,President,CEO):
Okay.SoIthinkIgotaboutfivepartsquestioninthere.IthinkI'lltrytogetthemall.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page18of22
Onthequestionofanimalhealth.Animalhealthperformedreasonable,butitdidhaveaproblem.Theproblemwasthat--itwasMerial.Merial'sinfluenceontwopartsofit.Onepartofitwasclearlytheintroductionofthatsecondstorebrandequivalentproductthatwhichwebelieved--continuetobelieveisabreachofouragreement.We'llfindout.Andplaythatoutinthecourtsystematsomepointintothefuture.
Thesecondpartoftheanimalhealthstoryisa--it'sa--theyalsohadsomecontractmanufacturingbusiness.Thatispartofwhatwesaw.
Thebasebusinessthoughintermsofwhatwedoeveryday,storebrand,sellingourfipronilplusproduct,continuestoperformwell.Butwedohavesomethingswehavetooffset.
Onthequestionoftheswitchovers.Weexpecttoseemoreproductscontinuetogoover-the-counter,beavailableforustermsoffleaandtickproducts.AndtheteamisdoingagoodjobtogettheequivalentofthoseproductsintothemarketplaceandtocontinuetorefreshthatpipelineofR&Deffortsonthepetcareside.
Onthequestionofthedoingadditional--Ithinkthispartwasadditionalbolt-onsfortheU.S.business.Weclearlythinktherewasmoreopportunitythere.Andthenthesecondpart?
AnnabelE.Samimy(Analyst-Stifel,Nicolaus&Co):
AreyouprioritizingOmegaoverthebolt-onsintheU.S.Iguess?
JosephC.Papa(Chairman,President,CEO):
Idon'tthink--thegoodnewsisIdon'tthinkweneedtoprioritize.Wellwehavetoclearlyprioritize.Ishouldsaythat.Wehavetoprioritize.
ButIthinkwehavetheresourcesnowtodoboth.IthinkwithwhatwecandoinbothintheEuropeanplatformandtheU.S.platform,wehavethecapabilitiesbasedoncashflow.But,Judy,whydon'tyoucommentonthatpart?
JudyL.Brown (CFO,EVP):
AndthenontheOmegamodelingquestionintheguidance.AsIsaidthesecondquarteristhe--theJunequarteristhelargestquarterfortheyear,aslowerSeptemberquarterwiththesummermonthsandsummerholidays,peoplebeingawayfromhome.Butcombinedwiththeexpectationthatwewouldexpecttobeclosingonourtworecently-announcedacquisitionsinthatSeptemberquarter,whichthenmeansthatwehavesaidwehaveputapproximately$25millionofsalesassociatedwiththecombinationofthosetwotransactionsinthefourthquarteroftheyear.
Sothereisinfactanamountof$25millionincludedintheguidanceandinourforecastforthosetwoacquisitionsandOmega.
AnnabelE.Samimy(Analyst-Stifel,Nicolaus&Co):
Thanks.
JudyL.Brown (CFO,EVP):
Yeah.
JosephC.Papa(Chairman,President,CEO):
Operatornextquestion?
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page19of22
Operator :
YournextquestioncomesfromDavidRisingerfromMorganStanley.
EmilChen (Analyst-MorganStanley&Co):
Hi.ThisisactuallyEmilonforDave.Justaquickquestion.Youmentionedpriorityinconsumer.Canyoudiscusstheprioritizationintermsofinorganicversusorganic?Doyouguysviewinthesethatyouneedtodosomethinginorganicallyinthenearterm,especiallyagainstthestockoutof$1billionoverthenext3yearsorganically?Thankyou.
JosephC.Papa(Chairman,President,CEO):
WellIthinkprobablythebestwayIcan--Ianswerthatquestionisbasedonourhistory.Ithinkwe'vealwayssoughttohaveabalanceofboththeorganicandinorganicinourgrowth.AndIthinkwe'llcontinuetolookatthat.
Wethinkdoingbothisreallythebestanswerforanycompanyoutthere.Sowe'llseektodotheinorganictobeclear,lookingatthosebolt-ontransactions.Wethinkthey'reveryvaluableandveryaccretivetoourshareholders.Sowe'llcontinuetolookatthose.
ButtheimportantcommentaboutwhatwedoeverydayhereatPerrigoistrytofindaqualityproduct,makeitmoreaffordable,anduseourresearchanddevelopmenteffortstocomeoutwiththenewproductflow.ImeanIthinkjustmycommentaryonnewproductsforusisreallycritical.AsIsaidI--tomyrecollectionthisisanall-timerecordofhavinginoneweekthreeANDAapprovalsfromtheFDA.
Butlookatwhattheyare.Theyareproductsthat--AndroGel1.62%,firsttofile.Advilfastrelease,toourknowledgealsofirsttofile,andcertainlywillbeouttherefirstapprovalforsure.Omeprazolemagnesium,yes,welaunchedanomeprazolebaseproductintothemarketplacegoingbacknowalmost7yearsago.Butwearenotcontenttojustsitthere.Andwewanttocontinuetogoafterthenationalbrandequivalent.
Wehavethoseopportunities.We'regoingtocontinuetotakethemtomakesurewemakeaqualityproduct,makeitmoreaffordableforsociety,bothhereintheUnitedStatesandaroundtheworld.Andthat'swhatwethinkisreallyexcitingandmotivatingtousasacompany.
OperatorIthinkIhavetimeformaybeonemorequestion.
Operator :
OurnextquestioncomesfromJamiRubinfromGoldmanSachs.
JamiRubin (Analyst-GoldmanSachs&Co):
Thankyou.Judy,Ihaveaquestionforyouandthenafollow-upforyou,Joe.
Whenyoutalkedaboutthesecondhalfoftheyearwitheachofthebusinesses,youthrewalittlebitofcoldwaterintermsofexpectinghigherexpenses,lowermargins,etcetera.Orthatsecondquarterwassortofapeak.
Areyoublessingthelowerendofthe$7.50to$8guidancerange?Andwhatdoesmakeup--whatis--whatarethekeyvariablestothat$0.50difference?
Andthenjust,Joe,afollow-upandmaybethisisnotafairquestion.ButIthinkwe'realltryingtogetat
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page20of22
this.IntheabsenceofawhiteknightinvestorforPerrigo,howdoyoudriveupsidetoyoursharepriceasastandalonecompany?Justbasedonconsensusestimatesthestocktradesata24multiplenowonthisyear'searnings,a22multipleonnextyear's,whichiscomparabletoCelgene.
Andclearlywhileyou'vedoneagreatjobwithdealactivityandtoplinegrowth,ifyoustripoutOmegatherewasnotoplinegrowththisquarter.SohowdoyouthinkaboutdrivingupsidefromamultipleashighasitisintheabsenceofconsolidationwherePerrigoisinvolved?Thanks.
JudyL.Brown (CFO,EVP):
Iwilltakeyourfirstpartfirst.SoIneverliketothrowcoldwateronanything,that'ssuchadowner.Ijustwantedto...
JamiRubin (Analyst-GoldmanSachs&Co):
Wellthisisyouropportunitytoclarifythat.Thankyou.
JudyL.Brown (CFO,EVP):
Allright.Allsunshine.Sojustwantedtomakesurethateveryonehadalineofsightinhelpingyoubeabletomodel.Becauseasyouknowwedon'tgooutandgivedetailedquarterlyguidance.Wetrytogiveyouanideaofhowtoshapethearcoftheyear.Andalsowehavethisnewvernacularaswe'reswitchingoverandgoingintocalendaryearmode.
Ifyouweretolayout,asI'msureyouhaveinyourmodels,theoverallmargindynamicsforourcomponentbusinesses,youseetheseasonalityreallyreflectedmoreinconsumerfacingbusinesses,justbecauseofconsumerfacingbehavior.Andwe'recertainlyseeingthisinOmegaaswell.IsthattheJunequarterishistoricallythehighestquarter.There'sjustalotofvolumemovementthroughtheplants,aswebotharesellingthroughaswellaspreparingforfalllaunches.
Youseeslower,typicallyslowersalesintheSeptemberquarter,becauseofthevacationseason,whichisevenexacerbatedandseenmoreinournewEuropeanbusiness.Andit'sjustimportant--alsowehavealotofactivitiesgoingonusuallyinrampingupwithnewlinesandnewproductionintheendoftheDecemberquartertypically.Sotherearemanynormalrecurringbehaviorsthatgooninthesecond6monthsofanycalendaryear.
Anditwasalsoveryimportant,Ihadtocallout,justbecauseoftheinclusionnowofOmegainourpoolofearningsbeforetax,thatifyourmodelhadhad17%effectivetaxrateforeveryquarter,ourmodelhas18.5%inthebackhalfofthecalendaryear.BecauseofthisdynamicasIsaidbeforeabouttherequirementindoingtheaccounting--veryboringaccountingdiscussionhere--ofhowonemustbookeffectivetaxrate.Youhavetotaketheblendedrate,forecastedforthereportingperiod.Andasyouknow,becausewe'reinthisstubyeartransition,theU.S.GAAP--quote--fullyearreportingisthe6-monthstubperiodendingDecember.Sothatstubperiodaccountingwillbemoreatan18.5%range.
Sothatiswhyjusttogiveyoucoloronhowtothinkabouttheshapeofthefull12monthsandtheseasonalitytherein.ThatiswhyIwantedto--itsoundedlikecoldwater--butjustmakingsureyouhadacrispwayofviewing.Sothatyouweren'toverstatingorgettingaheadofjusttheshapeoftheyearandconfirmingtheguidancethatwe'veprovidedalready.
JosephC.Papa(Chairman,President,CEO):
Onyourfirstpart--orsecondpartofyourquestion,Jami,theissueformereallygoesbacktohowdowecontinue--asastandalonecompanyhowdowecontinuetobesuccessful?AndIthinkreallythebestwaytosayitisit'sthatBasePlusPlusPlusapproach.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page21of22
Lookingatwhatwe'retalkingaboutthere.Clearlynewproducts.JustgettingthreenewapprovalsthisweekIthinkjustisagreatillustrativeexampleofwhatwe--whywe'reexcitedaboutit,whywethink--ifIcouldadd$1billionofnewproductsoverthenext3yearsintoourportfolio,wethinkthat'sgoingtobeanimportantpartofdrivingbothtoplineandourbottomline,becauseasyouknowournewproductstendtobemoreprofitable.
Numbertwo,Iknowthatclearlywealwayslookatquarterversusayearago.Butifyouthinkaboutwhatwe'vedonesequentially,ourConsumerHealthcarebusinessisup$61millionorapproximately9%sequentiallyifyougofromquarteronetoquartertwo.SoIknowthatthat'snotalwaysthewayyoulookatit.ButIdothinksequentialisanotherimportantpartoftheconsiderationastermsofthedirectionofwhatwe'retryingtoaccomplish.
Numberthree,formethisisthefirstquarterthatwe'vehadachancetotalkaboutOmega.Omegawethinkistremendouslyimportanttoourfutureandwhatwe'relookingtotrytoaccomplishaswetakethosebusinessesandwegettherevenuesynergiesandthecostofgoodssoldsynergiesinOmega.Wethinkthat'sgoingtobeanimportantpartofit.AndobviouslyasJudytalkedaboutthebusinesshasdonequitewellinthequarter.AndweexpecttoseegreatthingsfromOmega.
FinalcommentIofferanditreallyis--itreflectsonalsoonwhatJudywastalkingaboutforourcashgeneration.We'regeneratingasignificantamountofcash.WeintendtoputthatcashbacktoworkinM&A.Expecttoseemoreofthebolt-ontransactionsthatwethinkaregoingtobeveryaccretivetoourshareholders.Andwebelievethat'sgoingtohelpustremendously.NotjusttheGSKasset,theYokebeasset,buttheotherassetsthatwethinkareoutthereandwillfitverygoodwithbothourEuropeanbusinessesaswellasourU.S.business.
Sothat'stheexcitementwesee.That'swhywe'reverypassionateaboutourstandalonebusinessandwhatwethinkaregreatprospectsforthefuture.
JosephC.Papa(Chairman,President,CEO):
Operator,thankyouverymuch.Everyone,thankyouverymuchforyourinteresttoday.Weappreciateit.
Ifthere'sanyother--we'llhaveachancetofollow-upoverthenextdaysandweeksahead.Ifthere'sanyquestions,pleasegetintouchwithArtShannonorBradJoseph,whowillbehappytotrytoansweranythingfurther.
Haveagreatday,everyone.
Operator :
Thisistheendoftoday'scall.
Allrightsreserved(c)2014TheStreet,Inc.
Pleasefeelfreetoquoteupto200wordspertranscript.Anyquoteshouldbeaccompaniedby"ProvidedbyTheStreet"andalinktothecompletetranscriptandwww.thestreet.com.Anyotheruseormethodofdistributionisstrictlyprohibited.
THEINFORMATIONCONTAINEDINEACHWRITTENORAUDIOTRANSCRIPT(the"TRANSCRIPT")ISAREPRODUCTIONOFAPARTICULARCOMPANY'SCONFERENCECALL,CONFERENCEPRESENTATIONOROTHERAUDIOPRESENTATION.THETRANSCRIPTSAREPROVIDED"ASIS"AND"ASAVAILABLE"ANDTHESTREETISNOTRESPONSIBLEINANYWAYNORDOESITMAKEANYREPRESENTATIONORWARRANTYREGARDINGTHEACCURACYORCOMPLETENESSOFTHETRANSCRIPTSASPRODUCED,NORTHESUBSTANCEOFAPARTICULARCOMPANY'SINFORMATION.
CompanyName:PerrigoCoPLCCompanyTicker:PRGOSector:HealthCareIndustry:Drugs
EventDescription:Q22015EarningsCallMarketCapasofEventDate:28.16BPriceasofEventDate:189.65
©2014TheStreet,Inc.Al l R ightsReserved Page22of22
THETRANSCRIPTSAREPROVIDEDFORINFORMATIONALPURPOSESONLY.THESTREETISNOTPROVIDINGANYINVESTMENTADVICEORENDORSINGANYPARTICULARCOMPANY.